In the present study, we report the elucidation of the molecular mechanism of action of CA on both the brain tumors, GBM with p53 mutation which is observed in majority of GBMs and LGGs, as there is a need to evaluate the cell entities affected to consider CA as a potential option for future treatment with the anticipation of less side effects. Here, TP53 is linked to glioblastoma.